GlassScriptPhysician profile
Aruna Mishra
NPI 1396919007
$1,356.39
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $262 · 2021: $164 · 2022: $91.88 · 2023: $142 · 2024: $75.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $330.46 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $179.90 | 2019-2024 | Keytruda |
| Davol INC. | $167.94 | 2020-2021 | |
| Heron Therapeutics, INC. | $142.24 | 2023 | Zynrelef |
| Astrazeneca Pharmaceuticals LP | $128.84 | 2019 | |
| Sage Therapeutics, LLC | $96.65 | 2020 | |
| Gilead Sciences, INC. | $95.16 | 2019 | |
| Applied Medical Resources Corporation | $62.73 | 2022 | |
| Coopersurgical, INC. | $40.36 | 2019 | |
| Hologic Sales and Service, LLC | $33.42 | 2024 | Thinprep 2000 Processor |
| Organon LLC | $29.15 | 2022 | |
| Sumitomo Pharma America, INC. | $18.75 | 2024 | Myfembree |
| Therapeuticsmd, INC. | $17.97 | 2021 | |
| Myovant Sciences INC. | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Mishra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.